nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—Protein Kinase Inhibitors—Vemurafenib—skin cancer	0.43	0.58	CiPCiCtD
Everolimus—P-Glycoprotein Inhibitors—Vemurafenib—skin cancer	0.311	0.42	CiPCiCtD
Everolimus—CYP3A4—Temozolomide—skin cancer	0.0296	0.292	CbGbCtD
Everolimus—CYP3A4—Imiquimod—skin cancer	0.0296	0.292	CbGbCtD
Everolimus—CYP3A4—Vismodegib—skin cancer	0.0205	0.202	CbGbCtD
Everolimus—CYP3A4—Vemurafenib—skin cancer	0.0162	0.16	CbGbCtD
Everolimus—CYP3A4—Docetaxel—skin cancer	0.00556	0.0548	CbGbCtD
Everolimus—MTOR—leg—skin cancer	0.00465	0.133	CbGeAlD
Everolimus—MTOR—forelimb—skin cancer	0.00461	0.132	CbGeAlD
Everolimus—MTOR—hindlimb—skin cancer	0.00415	0.119	CbGeAlD
Everolimus—MTOR—appendage—skin cancer	0.00356	0.102	CbGeAlD
Everolimus—MTOR—blood vessel—skin cancer	0.00198	0.0567	CbGeAlD
Everolimus—MTOR—neck—skin cancer	0.00142	0.0406	CbGeAlD
Everolimus—FKBP1A—nipple—skin cancer	0.00129	0.0369	CbGeAlD
Everolimus—FKBP1A—neck—skin cancer	0.00127	0.0365	CbGeAlD
Everolimus—MTOR—connective tissue—skin cancer	0.00102	0.0291	CbGeAlD
Everolimus—MTOR—epithelium—skin cancer	0.000964	0.0276	CbGeAlD
Everolimus—MTOR—skin of body—skin cancer	0.000917	0.0263	CbGeAlD
Everolimus—FKBP1A—connective tissue—skin cancer	0.000914	0.0262	CbGeAlD
Everolimus—FKBP1A—epithelium—skin cancer	0.000867	0.0248	CbGeAlD
Everolimus—MTOR—mammalian vulva—skin cancer	0.000837	0.0239	CbGeAlD
Everolimus—FKBP1A—skin of body—skin cancer	0.000825	0.0236	CbGeAlD
Everolimus—FKBP1A—mammalian vulva—skin cancer	0.000752	0.0215	CbGeAlD
Everolimus—MTOR—lymphoid tissue—skin cancer	0.000743	0.0213	CbGeAlD
Everolimus—MTOR—female reproductive system—skin cancer	0.000716	0.0205	CbGeAlD
Everolimus—FKBP1A—lymphoid tissue—skin cancer	0.000668	0.0191	CbGeAlD
Everolimus—FKBP1A—female reproductive system—skin cancer	0.000644	0.0184	CbGeAlD
Everolimus—MTOR—head—skin cancer	0.000599	0.0171	CbGeAlD
Everolimus—FKBP1A—head—skin cancer	0.000538	0.0154	CbGeAlD
Everolimus—MTOR—lymph node—skin cancer	0.000419	0.012	CbGeAlD
Everolimus—FKBP1A—lymph node—skin cancer	0.000377	0.0108	CbGeAlD
Everolimus—CYP3A4—female reproductive system—skin cancer	0.000211	0.00603	CbGeAlD
Everolimus—MTOR—Signaling by FGFR—FOXO4—skin cancer	0.000106	0.00684	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—FOXO4—skin cancer	0.000106	0.00684	CbGpPWpGaD
Everolimus—MTOR—ErbB2/ErbB3 signaling events—NRAS—skin cancer	0.000106	0.00683	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—FOXO4—skin cancer	0.000105	0.00681	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—FOXO4—skin cancer	0.000105	0.00678	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—PTGS2—skin cancer	0.000104	0.0067	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FOXO4—skin cancer	0.000103	0.00668	CbGpPWpGaD
Everolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—HRAS—skin cancer	9.93e-05	0.00641	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	9.88e-05	0.00638	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FOXO4—skin cancer	9.87e-05	0.00638	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—FOXO4—skin cancer	9.87e-05	0.00638	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—FOXO4—skin cancer	9.87e-05	0.00638	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—FOXO4—skin cancer	9.79e-05	0.00632	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—FOXO4—skin cancer	9.7e-05	0.00626	CbGpPWpGaD
Everolimus—MTOR—CXCR3-mediated signaling events—KRAS—skin cancer	9.67e-05	0.00625	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—FOXO4—skin cancer	9.66e-05	0.00624	CbGpPWpGaD
Everolimus—MTOR—Alpha 6 Beta 4 signaling pathway—HRAS—skin cancer	9.21e-05	0.00594	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—FOXO4—skin cancer	9.14e-05	0.0059	CbGpPWpGaD
Everolimus—MTOR—ErbB2/ErbB3 signaling events—KRAS—skin cancer	9.1e-05	0.00588	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FOXO4—skin cancer	8.75e-05	0.00565	CbGpPWpGaD
Everolimus—MTOR—CXCR3-mediated signaling events—HRAS—skin cancer	8.22e-05	0.00531	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—BRAF—skin cancer	7.93e-05	0.00512	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—BRAF—skin cancer	7.93e-05	0.00512	CbGpPWpGaD
Everolimus—MTOR—LKB1 signaling events—TP53—skin cancer	7.79e-05	0.00503	CbGpPWpGaD
Everolimus—MTOR—ErbB2/ErbB3 signaling events—HRAS—skin cancer	7.74e-05	0.005	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—TLR7—skin cancer	7.45e-05	0.00481	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—KRAS—skin cancer	7.3e-05	0.00472	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—NRAS—skin cancer	7.23e-05	0.00467	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	7.06e-05	0.00456	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RHOU—skin cancer	7.04e-05	0.00455	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—CDKN2A—skin cancer	6.85e-05	0.00442	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—FOXO4—skin cancer	6.73e-05	0.00434	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—CDK4—skin cancer	6.7e-05	0.00433	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—IL6—skin cancer	6.64e-05	0.00429	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CSPG4—skin cancer	6.62e-05	0.00427	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—TP53—skin cancer	6.49e-05	0.00419	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—KRAS—skin cancer	6.3e-05	0.00407	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—KRAS—skin cancer	6.22e-05	0.00402	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—HRAS—skin cancer	6.21e-05	0.00401	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—skin cancer	6.18e-05	0.00399	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTCH2—skin cancer	6.12e-05	0.00395	CbGpPWpGaD
Everolimus—Chills—Temozolomide—skin cancer	5.93e-05	0.000549	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—BRAF—skin cancer	5.93e-05	0.00383	CbGpPWpGaD
Everolimus—Dehydration—Docetaxel—skin cancer	5.91e-05	0.000547	CcSEcCtD
Everolimus—Ill-defined disorder—Dactinomycin—skin cancer	5.9e-05	0.000547	CcSEcCtD
Everolimus—MTOR—IRS-mediated signalling—NRAS—skin cancer	5.9e-05	0.00381	CbGpPWpGaD
Everolimus—Anaemia—Dactinomycin—skin cancer	5.88e-05	0.000545	CcSEcCtD
Everolimus—Liver function test abnormal—Docetaxel—skin cancer	5.87e-05	0.000543	CcSEcCtD
Everolimus—Vomiting—Vemurafenib—skin cancer	5.84e-05	0.000541	CcSEcCtD
Everolimus—Alopecia—Temozolomide—skin cancer	5.84e-05	0.000541	CcSEcCtD
Everolimus—Dry skin—Docetaxel—skin cancer	5.83e-05	0.000539	CcSEcCtD
Everolimus—Myalgia—Bleomycin—skin cancer	5.81e-05	0.000538	CcSEcCtD
Everolimus—Chest pain—Bleomycin—skin cancer	5.81e-05	0.000538	CcSEcCtD
Everolimus—Abdominal pain upper—Docetaxel—skin cancer	5.81e-05	0.000537	CcSEcCtD
Everolimus—Rash—Vemurafenib—skin cancer	5.8e-05	0.000537	CcSEcCtD
Everolimus—Mental disorder—Temozolomide—skin cancer	5.79e-05	0.000536	CcSEcCtD
Everolimus—Dermatitis—Vemurafenib—skin cancer	5.79e-05	0.000536	CcSEcCtD
Everolimus—Hypersensitivity—Imiquimod—skin cancer	5.78e-05	0.000535	CcSEcCtD
Everolimus—Headache—Vemurafenib—skin cancer	5.76e-05	0.000533	CcSEcCtD
Everolimus—Malnutrition—Temozolomide—skin cancer	5.76e-05	0.000533	CcSEcCtD
Everolimus—Erythema—Temozolomide—skin cancer	5.76e-05	0.000533	CcSEcCtD
Everolimus—Breast disorder—Docetaxel—skin cancer	5.74e-05	0.000532	CcSEcCtD
Everolimus—MTOR—IRS-related events—NRAS—skin cancer	5.74e-05	0.00371	CbGpPWpGaD
Everolimus—Discomfort—Bleomycin—skin cancer	5.74e-05	0.000531	CcSEcCtD
Everolimus—Malaise—Dactinomycin—skin cancer	5.74e-05	0.000531	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Docetaxel—skin cancer	5.72e-05	0.00053	CcSEcCtD
Everolimus—Leukopenia—Dactinomycin—skin cancer	5.7e-05	0.000527	CcSEcCtD
Everolimus—MTOR—IRS-related events triggered by IGF1R—NRAS—skin cancer	5.69e-05	0.00367	CbGpPWpGaD
Everolimus—Nasopharyngitis—Docetaxel—skin cancer	5.68e-05	0.000526	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—IL6—skin cancer	5.65e-05	0.00365	CbGpPWpGaD
Everolimus—Dysgeusia—Temozolomide—skin cancer	5.64e-05	0.000522	CcSEcCtD
Everolimus—Asthenia—Imiquimod—skin cancer	5.62e-05	0.000521	CcSEcCtD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—BRAF—skin cancer	5.61e-05	0.00362	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—BRAF—skin cancer	5.61e-05	0.00362	CbGpPWpGaD
Everolimus—Alanine aminotransferase increased—Docetaxel—skin cancer	5.61e-05	0.000519	CcSEcCtD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—skin cancer	5.6e-05	0.00361	CbGpPWpGaD
Everolimus—Oedema—Bleomycin—skin cancer	5.57e-05	0.000516	CcSEcCtD
Everolimus—Back pain—Temozolomide—skin cancer	5.57e-05	0.000515	CcSEcCtD
Everolimus—Pruritus—Imiquimod—skin cancer	5.55e-05	0.000513	CcSEcCtD
Everolimus—MTOR—Insulin receptor signalling cascade—NRAS—skin cancer	5.54e-05	0.00358	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—NRAS—skin cancer	5.54e-05	0.00358	CbGpPWpGaD
Everolimus—Infection—Bleomycin—skin cancer	5.53e-05	0.000512	CcSEcCtD
Everolimus—Dysphagia—Docetaxel—skin cancer	5.49e-05	0.000509	CcSEcCtD
Everolimus—Nausea—Vemurafenib—skin cancer	5.46e-05	0.000505	CcSEcCtD
Everolimus—Thrombocytopenia—Bleomycin—skin cancer	5.45e-05	0.000505	CcSEcCtD
Everolimus—Vision blurred—Temozolomide—skin cancer	5.42e-05	0.000502	CcSEcCtD
Everolimus—Myalgia—Dactinomycin—skin cancer	5.42e-05	0.000502	CcSEcCtD
Everolimus—Bronchospasm—Docetaxel—skin cancer	5.4e-05	0.0005	CcSEcCtD
Everolimus—Tremor—Temozolomide—skin cancer	5.39e-05	0.000499	CcSEcCtD
Everolimus—Alopecia—Fluorouracil—skin cancer	5.38e-05	0.000498	CcSEcCtD
Everolimus—Diarrhoea—Imiquimod—skin cancer	5.36e-05	0.000497	CcSEcCtD
Everolimus—Discomfort—Dactinomycin—skin cancer	5.35e-05	0.000496	CcSEcCtD
Everolimus—MTOR—Oncostatin M Signaling Pathway—HRAS—skin cancer	5.35e-05	0.00346	CbGpPWpGaD
Everolimus—Angina pectoris—Docetaxel—skin cancer	5.35e-05	0.000495	CcSEcCtD
Everolimus—Ill-defined disorder—Temozolomide—skin cancer	5.34e-05	0.000494	CcSEcCtD
Everolimus—MTOR—AMPK Signaling—TP53—skin cancer	5.34e-05	0.00344	CbGpPWpGaD
Everolimus—Anaemia—Temozolomide—skin cancer	5.32e-05	0.000492	CcSEcCtD
Everolimus—Anorexia—Bleomycin—skin cancer	5.31e-05	0.000491	CcSEcCtD
Everolimus—Erythema—Fluorouracil—skin cancer	5.3e-05	0.000491	CcSEcCtD
Everolimus—Agitation—Temozolomide—skin cancer	5.29e-05	0.00049	CcSEcCtD
Everolimus—MTOR—TSH signaling pathway—HRAS—skin cancer	5.29e-05	0.00341	CbGpPWpGaD
Everolimus—MTOR—mTOR signaling pathway—HRAS—skin cancer	5.29e-05	0.00341	CbGpPWpGaD
Everolimus—Angioedema—Temozolomide—skin cancer	5.26e-05	0.000487	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR in disease—BRAF—skin cancer	5.22e-05	0.00337	CbGpPWpGaD
Everolimus—Pancytopenia—Docetaxel—skin cancer	5.22e-05	0.000483	CcSEcCtD
Everolimus—Hypotension—Bleomycin—skin cancer	5.2e-05	0.000482	CcSEcCtD
Everolimus—Oedema—Dactinomycin—skin cancer	5.19e-05	0.000481	CcSEcCtD
Everolimus—Malaise—Temozolomide—skin cancer	5.19e-05	0.000481	CcSEcCtD
Everolimus—Dizziness—Imiquimod—skin cancer	5.18e-05	0.00048	CcSEcCtD
Everolimus—Infection—Dactinomycin—skin cancer	5.16e-05	0.000478	CcSEcCtD
Everolimus—Leukopenia—Temozolomide—skin cancer	5.15e-05	0.000477	CcSEcCtD
Everolimus—Neutropenia—Docetaxel—skin cancer	5.14e-05	0.000476	CcSEcCtD
Everolimus—Palpitations—Temozolomide—skin cancer	5.09e-05	0.000471	CcSEcCtD
Everolimus—Thrombocytopenia—Dactinomycin—skin cancer	5.09e-05	0.000471	CcSEcCtD
Everolimus—MTOR—IRS-mediated signalling—KRAS—skin cancer	5.08e-05	0.00328	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Bleomycin—skin cancer	5.07e-05	0.00047	CcSEcCtD
Everolimus—MTOR—CDC42 signaling events—HRAS—skin cancer	5.04e-05	0.00326	CbGpPWpGaD
Everolimus—Cough—Temozolomide—skin cancer	5.02e-05	0.000465	CcSEcCtD
Everolimus—Paraesthesia—Bleomycin—skin cancer	5e-05	0.000463	CcSEcCtD
Everolimus—Vision blurred—Fluorouracil—skin cancer	5e-05	0.000463	CcSEcCtD
Everolimus—Convulsion—Temozolomide—skin cancer	4.99e-05	0.000462	CcSEcCtD
Everolimus—MTOR—ErbB1 downstream signaling—NRAS—skin cancer	4.98e-05	0.00322	CbGpPWpGaD
Everolimus—Vomiting—Imiquimod—skin cancer	4.98e-05	0.000461	CcSEcCtD
Everolimus—Weight decreased—Docetaxel—skin cancer	4.97e-05	0.00046	CcSEcCtD
Everolimus—Hypertension—Temozolomide—skin cancer	4.97e-05	0.00046	CcSEcCtD
Everolimus—Dyspnoea—Bleomycin—skin cancer	4.96e-05	0.00046	CcSEcCtD
Everolimus—Anorexia—Dactinomycin—skin cancer	4.95e-05	0.000458	CcSEcCtD
Everolimus—Rash—Imiquimod—skin cancer	4.94e-05	0.000458	CcSEcCtD
Everolimus—MTOR—IRS-related events—KRAS—skin cancer	4.94e-05	0.00319	CbGpPWpGaD
Everolimus—Dermatitis—Imiquimod—skin cancer	4.94e-05	0.000457	CcSEcCtD
Everolimus—Pneumonia—Docetaxel—skin cancer	4.93e-05	0.000456	CcSEcCtD
Everolimus—Headache—Imiquimod—skin cancer	4.91e-05	0.000455	CcSEcCtD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—NRAS—skin cancer	4.91e-05	0.00317	CbGpPWpGaD
Everolimus—Anaemia—Fluorouracil—skin cancer	4.9e-05	0.000454	CcSEcCtD
Everolimus—Myalgia—Temozolomide—skin cancer	4.9e-05	0.000454	CcSEcCtD
Everolimus—Arthralgia—Temozolomide—skin cancer	4.9e-05	0.000454	CcSEcCtD
Everolimus—Infestation NOS—Docetaxel—skin cancer	4.9e-05	0.000453	CcSEcCtD
Everolimus—Infestation—Docetaxel—skin cancer	4.9e-05	0.000453	CcSEcCtD
Everolimus—MTOR—IRS-related events triggered by IGF1R—KRAS—skin cancer	4.9e-05	0.00316	CbGpPWpGaD
Everolimus—Anxiety—Temozolomide—skin cancer	4.88e-05	0.000452	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	4.87e-05	0.000451	CcSEcCtD
Everolimus—Discomfort—Temozolomide—skin cancer	4.84e-05	0.000448	CcSEcCtD
Everolimus—Decreased appetite—Bleomycin—skin cancer	4.84e-05	0.000448	CcSEcCtD
Everolimus—Acute coronary syndrome—Docetaxel—skin cancer	4.83e-05	0.000447	CcSEcCtD
Everolimus—Renal failure—Docetaxel—skin cancer	4.81e-05	0.000446	CcSEcCtD
Everolimus—Myocardial infarction—Docetaxel—skin cancer	4.8e-05	0.000444	CcSEcCtD
Everolimus—Dry mouth—Temozolomide—skin cancer	4.79e-05	0.000444	CcSEcCtD
Everolimus—Stomatitis—Docetaxel—skin cancer	4.77e-05	0.000442	CcSEcCtD
Everolimus—Jaundice—Docetaxel—skin cancer	4.77e-05	0.000442	CcSEcCtD
Everolimus—MTOR—Leptin signaling pathway—HRAS—skin cancer	4.77e-05	0.00308	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—KRAS—skin cancer	4.77e-05	0.00308	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—KRAS—skin cancer	4.77e-05	0.00308	CbGpPWpGaD
Everolimus—Pain—Bleomycin—skin cancer	4.76e-05	0.000441	CcSEcCtD
Everolimus—Conjunctivitis—Docetaxel—skin cancer	4.76e-05	0.000441	CcSEcCtD
Everolimus—Leukopenia—Fluorouracil—skin cancer	4.75e-05	0.000439	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Dactinomycin—skin cancer	4.73e-05	0.000438	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	4.73e-05	0.00305	CbGpPWpGaD
Everolimus—Oedema—Temozolomide—skin cancer	4.7e-05	0.000435	CcSEcCtD
Everolimus—Infection—Temozolomide—skin cancer	4.67e-05	0.000432	CcSEcCtD
Everolimus—Nausea—Imiquimod—skin cancer	4.66e-05	0.000431	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—GLI2—skin cancer	4.64e-05	0.00299	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—NRAS—skin cancer	4.63e-05	0.00299	CbGpPWpGaD
Everolimus—Hepatobiliary disease—Docetaxel—skin cancer	4.63e-05	0.000429	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—BRAF—skin cancer	4.63e-05	0.00299	CbGpPWpGaD
Everolimus—Epistaxis—Docetaxel—skin cancer	4.62e-05	0.000428	CcSEcCtD
Everolimus—Nervous system disorder—Temozolomide—skin cancer	4.61e-05	0.000426	CcSEcCtD
Everolimus—MTOR—Signaling by Insulin receptor—NRAS—skin cancer	4.6e-05	0.00297	CbGpPWpGaD
Everolimus—Thrombocytopenia—Temozolomide—skin cancer	4.6e-05	0.000426	CcSEcCtD
Everolimus—Convulsion—Fluorouracil—skin cancer	4.59e-05	0.000425	CcSEcCtD
Everolimus—Feeling abnormal—Bleomycin—skin cancer	4.59e-05	0.000425	CcSEcCtD
Everolimus—Skin disorder—Temozolomide—skin cancer	4.56e-05	0.000422	CcSEcCtD
Everolimus—Hyperhidrosis—Temozolomide—skin cancer	4.54e-05	0.00042	CcSEcCtD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—HRAS—skin cancer	4.53e-05	0.00293	CbGpPWpGaD
Everolimus—Chest pain—Fluorouracil—skin cancer	4.52e-05	0.000418	CcSEcCtD
Everolimus—Myalgia—Fluorouracil—skin cancer	4.52e-05	0.000418	CcSEcCtD
Everolimus—Decreased appetite—Dactinomycin—skin cancer	4.51e-05	0.000418	CcSEcCtD
Everolimus—FKBP1A—Disease—SHH—skin cancer	4.5e-05	0.00291	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ENO2—skin cancer	4.5e-05	0.00291	CbGpPWpGaD
Everolimus—Fatigue—Dactinomycin—skin cancer	4.48e-05	0.000415	CcSEcCtD
Everolimus—Anorexia—Temozolomide—skin cancer	4.48e-05	0.000415	CcSEcCtD
Everolimus—Discomfort—Fluorouracil—skin cancer	4.46e-05	0.000413	CcSEcCtD
Everolimus—Pain—Dactinomycin—skin cancer	4.44e-05	0.000411	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—MC1R—skin cancer	4.42e-05	0.00286	CbGpPWpGaD
Everolimus—Haemoglobin—Docetaxel—skin cancer	4.42e-05	0.000409	CcSEcCtD
Everolimus—Rhinitis—Docetaxel—skin cancer	4.41e-05	0.000408	CcSEcCtD
Everolimus—Body temperature increased—Bleomycin—skin cancer	4.4e-05	0.000408	CcSEcCtD
Everolimus—Hepatitis—Docetaxel—skin cancer	4.4e-05	0.000407	CcSEcCtD
Everolimus—Haemorrhage—Docetaxel—skin cancer	4.4e-05	0.000407	CcSEcCtD
Everolimus—Hypoaesthesia—Docetaxel—skin cancer	4.38e-05	0.000405	CcSEcCtD
Everolimus—Pharyngitis—Docetaxel—skin cancer	4.36e-05	0.000404	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—GLI1—skin cancer	4.36e-05	0.00281	CbGpPWpGaD
Everolimus—Urinary tract disorder—Docetaxel—skin cancer	4.34e-05	0.000402	CcSEcCtD
Everolimus—MTOR—Immune System—TLR7—skin cancer	4.34e-05	0.0028	CbGpPWpGaD
Everolimus—Oedema peripheral—Docetaxel—skin cancer	4.33e-05	0.000401	CcSEcCtD
Everolimus—Oedema—Fluorouracil—skin cancer	4.33e-05	0.000401	CcSEcCtD
Everolimus—Connective tissue disorder—Docetaxel—skin cancer	4.32e-05	0.0004	CcSEcCtD
Everolimus—MTOR—IRS-mediated signalling—HRAS—skin cancer	4.32e-05	0.00279	CbGpPWpGaD
Everolimus—Urethral disorder—Docetaxel—skin cancer	4.31e-05	0.000399	CcSEcCtD
Everolimus—Infection—Fluorouracil—skin cancer	4.3e-05	0.000398	CcSEcCtD
Everolimus—MTOR—ErbB1 downstream signaling—KRAS—skin cancer	4.29e-05	0.00277	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CDK4—skin cancer	4.29e-05	0.00277	CbGpPWpGaD
Everolimus—Feeling abnormal—Dactinomycin—skin cancer	4.28e-05	0.000396	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Temozolomide—skin cancer	4.28e-05	0.000396	CcSEcCtD
Everolimus—Insomnia—Temozolomide—skin cancer	4.25e-05	0.000393	CcSEcCtD
Everolimus—Gastrointestinal pain—Dactinomycin—skin cancer	4.25e-05	0.000393	CcSEcCtD
Everolimus—Nervous system disorder—Fluorouracil—skin cancer	4.24e-05	0.000393	CcSEcCtD
Everolimus—Thrombocytopenia—Fluorouracil—skin cancer	4.24e-05	0.000392	CcSEcCtD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—KRAS—skin cancer	4.23e-05	0.00273	CbGpPWpGaD
Everolimus—Tachycardia—Fluorouracil—skin cancer	4.22e-05	0.000391	CcSEcCtD
Everolimus—Paraesthesia—Temozolomide—skin cancer	4.22e-05	0.00039	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	4.2e-05	0.00271	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—HRAS—skin cancer	4.2e-05	0.00271	CbGpPWpGaD
Everolimus—Dyspnoea—Temozolomide—skin cancer	4.19e-05	0.000388	CcSEcCtD
Everolimus—Somnolence—Temozolomide—skin cancer	4.18e-05	0.000387	CcSEcCtD
Everolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—skin cancer	4.16e-05	0.00269	CbGpPWpGaD
Everolimus—Dyspepsia—Temozolomide—skin cancer	4.14e-05	0.000383	CcSEcCtD
Everolimus—MTOR—IRS-mediated signalling—IL6—skin cancer	4.13e-05	0.00267	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SUFU—skin cancer	4.13e-05	0.00267	CbGpPWpGaD
Everolimus—Anorexia—Fluorouracil—skin cancer	4.13e-05	0.000382	CcSEcCtD
Everolimus—Eye disorder—Docetaxel—skin cancer	4.11e-05	0.00038	CcSEcCtD
Everolimus—Body temperature increased—Dactinomycin—skin cancer	4.11e-05	0.00038	CcSEcCtD
Everolimus—Abdominal pain—Dactinomycin—skin cancer	4.11e-05	0.00038	CcSEcCtD
Everolimus—Hypersensitivity—Bleomycin—skin cancer	4.1e-05	0.00038	CcSEcCtD
Everolimus—Decreased appetite—Temozolomide—skin cancer	4.08e-05	0.000378	CcSEcCtD
Everolimus—Flushing—Docetaxel—skin cancer	4.08e-05	0.000378	CcSEcCtD
Everolimus—Cardiac disorder—Docetaxel—skin cancer	4.08e-05	0.000378	CcSEcCtD
Everolimus—Gastrointestinal disorder—Temozolomide—skin cancer	4.06e-05	0.000375	CcSEcCtD
Everolimus—MTOR—Insulin receptor signalling cascade—HRAS—skin cancer	4.05e-05	0.00262	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—HRAS—skin cancer	4.05e-05	0.00262	CbGpPWpGaD
Everolimus—Fatigue—Temozolomide—skin cancer	4.05e-05	0.000375	CcSEcCtD
Everolimus—Hypotension—Fluorouracil—skin cancer	4.04e-05	0.000374	CcSEcCtD
Everolimus—MTOR—IRS-related events—IL6—skin cancer	4.02e-05	0.0026	CbGpPWpGaD
Everolimus—Constipation—Temozolomide—skin cancer	4.02e-05	0.000372	CcSEcCtD
Everolimus—Pain—Temozolomide—skin cancer	4.02e-05	0.000372	CcSEcCtD
Everolimus—Asthenia—Bleomycin—skin cancer	4e-05	0.00037	CcSEcCtD
Everolimus—Angiopathy—Docetaxel—skin cancer	3.99e-05	0.000369	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—KRAS—skin cancer	3.99e-05	0.00258	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—IL6—skin cancer	3.98e-05	0.00257	CbGpPWpGaD
Everolimus—Immune system disorder—Docetaxel—skin cancer	3.97e-05	0.000368	CcSEcCtD
Everolimus—Mediastinal disorder—Docetaxel—skin cancer	3.96e-05	0.000367	CcSEcCtD
Everolimus—MTOR—Signaling by Insulin receptor—KRAS—skin cancer	3.96e-05	0.00256	CbGpPWpGaD
Everolimus—Chills—Docetaxel—skin cancer	3.95e-05	0.000365	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Fluorouracil—skin cancer	3.94e-05	0.000365	CcSEcCtD
Everolimus—Pruritus—Bleomycin—skin cancer	3.94e-05	0.000365	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—NRAS—skin cancer	3.94e-05	0.00254	CbGpPWpGaD
Everolimus—Insomnia—Fluorouracil—skin cancer	3.91e-05	0.000362	CcSEcCtD
Everolimus—Paraesthesia—Fluorouracil—skin cancer	3.89e-05	0.00036	CcSEcCtD
Everolimus—Alopecia—Docetaxel—skin cancer	3.89e-05	0.00036	CcSEcCtD
Everolimus—MTOR—Insulin receptor signalling cascade—IL6—skin cancer	3.88e-05	0.0025	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—IL6—skin cancer	3.88e-05	0.0025	CbGpPWpGaD
Everolimus—Feeling abnormal—Temozolomide—skin cancer	3.87e-05	0.000358	CcSEcCtD
Everolimus—Dyspnoea—Fluorouracil—skin cancer	3.86e-05	0.000357	CcSEcCtD
Everolimus—Mental disorder—Docetaxel—skin cancer	3.85e-05	0.000357	CcSEcCtD
Everolimus—Somnolence—Fluorouracil—skin cancer	3.85e-05	0.000356	CcSEcCtD
Everolimus—Gastrointestinal pain—Temozolomide—skin cancer	3.84e-05	0.000356	CcSEcCtD
Everolimus—MTOR—Innate Immune System—FOXO4—skin cancer	3.84e-05	0.00248	CbGpPWpGaD
Everolimus—Malnutrition—Docetaxel—skin cancer	3.83e-05	0.000354	CcSEcCtD
Everolimus—Erythema—Docetaxel—skin cancer	3.83e-05	0.000354	CcSEcCtD
Everolimus—Hypersensitivity—Dactinomycin—skin cancer	3.83e-05	0.000354	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—skin cancer	3.81e-05	0.00246	CbGpPWpGaD
Everolimus—Dyspepsia—Fluorouracil—skin cancer	3.81e-05	0.000353	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—NRAS—skin cancer	3.77e-05	0.00243	CbGpPWpGaD
Everolimus—Decreased appetite—Fluorouracil—skin cancer	3.76e-05	0.000348	CcSEcCtD
Everolimus—Dysgeusia—Docetaxel—skin cancer	3.75e-05	0.000347	CcSEcCtD
Everolimus—Gastrointestinal disorder—Fluorouracil—skin cancer	3.74e-05	0.000346	CcSEcCtD
Everolimus—Asthenia—Dactinomycin—skin cancer	3.73e-05	0.000345	CcSEcCtD
Everolimus—MTOR—Disease—CSPG4—skin cancer	3.72e-05	0.0024	CbGpPWpGaD
Everolimus—Abdominal pain—Temozolomide—skin cancer	3.71e-05	0.000344	CcSEcCtD
Everolimus—Body temperature increased—Temozolomide—skin cancer	3.71e-05	0.000344	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—NRAS—skin cancer	3.71e-05	0.00239	CbGpPWpGaD
Everolimus—Back pain—Docetaxel—skin cancer	3.7e-05	0.000343	CcSEcCtD
Everolimus—Pain—Fluorouracil—skin cancer	3.7e-05	0.000343	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—FOXO4—skin cancer	3.68e-05	0.00238	CbGpPWpGaD
Everolimus—Muscle spasms—Docetaxel—skin cancer	3.68e-05	0.000341	CcSEcCtD
Everolimus—FKBP1A—Disease—FOXO4—skin cancer	3.67e-05	0.00237	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—HRAS—skin cancer	3.65e-05	0.00235	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—skin cancer	3.65e-05	0.00235	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—skin cancer	3.59e-05	0.00232	CbGpPWpGaD
Everolimus—Feeling abnormal—Fluorouracil—skin cancer	3.57e-05	0.00033	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—BRAF—skin cancer	3.56e-05	0.0023	CbGpPWpGaD
Everolimus—Diarrhoea—Dactinomycin—skin cancer	3.55e-05	0.000329	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—NRAS—skin cancer	3.54e-05	0.00229	CbGpPWpGaD
Everolimus—Vomiting—Bleomycin—skin cancer	3.54e-05	0.000328	CcSEcCtD
Everolimus—Anaemia—Docetaxel—skin cancer	3.54e-05	0.000328	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—NRAS—skin cancer	3.52e-05	0.00228	CbGpPWpGaD
Everolimus—Rash—Bleomycin—skin cancer	3.51e-05	0.000325	CcSEcCtD
Everolimus—Dermatitis—Bleomycin—skin cancer	3.51e-05	0.000325	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—NRAS—skin cancer	3.51e-05	0.00226	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—IL6—skin cancer	3.49e-05	0.00225	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—NRAS—skin cancer	3.49e-05	0.00225	CbGpPWpGaD
Everolimus—Hypersensitivity—Temozolomide—skin cancer	3.46e-05	0.00032	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—PTCH2—skin cancer	3.44e-05	0.00222	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—skin cancer	3.44e-05	0.00222	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—skin cancer	3.44e-05	0.00222	CbGpPWpGaD
Everolimus—Syncope—Docetaxel—skin cancer	3.43e-05	0.000318	CcSEcCtD
Everolimus—Leukopenia—Docetaxel—skin cancer	3.43e-05	0.000317	CcSEcCtD
Everolimus—Body temperature increased—Fluorouracil—skin cancer	3.42e-05	0.000317	CcSEcCtD
Everolimus—MTOR—Signaling by VEGF—HRAS—skin cancer	3.39e-05	0.00219	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—KRAS—skin cancer	3.39e-05	0.00219	CbGpPWpGaD
Everolimus—Palpitations—Docetaxel—skin cancer	3.38e-05	0.000313	CcSEcCtD
Everolimus—Asthenia—Temozolomide—skin cancer	3.37e-05	0.000312	CcSEcCtD
Everolimus—MTOR—Signaling by Insulin receptor—HRAS—skin cancer	3.37e-05	0.00217	CbGpPWpGaD
Everolimus—Loss of consciousness—Docetaxel—skin cancer	3.36e-05	0.000311	CcSEcCtD
Everolimus—Cough—Docetaxel—skin cancer	3.34e-05	0.000309	CcSEcCtD
Everolimus—Pruritus—Temozolomide—skin cancer	3.32e-05	0.000308	CcSEcCtD
Everolimus—Convulsion—Docetaxel—skin cancer	3.32e-05	0.000307	CcSEcCtD
Everolimus—Nausea—Bleomycin—skin cancer	3.31e-05	0.000306	CcSEcCtD
Everolimus—Hypertension—Docetaxel—skin cancer	3.3e-05	0.000306	CcSEcCtD
Everolimus—Vomiting—Dactinomycin—skin cancer	3.3e-05	0.000306	CcSEcCtD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—skin cancer	3.28e-05	0.00212	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—NRAS—skin cancer	3.28e-05	0.00212	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—NRAS—skin cancer	3.28e-05	0.00212	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CDKN2A—skin cancer	3.28e-05	0.00212	CbGpPWpGaD
Everolimus—Rash—Dactinomycin—skin cancer	3.27e-05	0.000303	CcSEcCtD
Everolimus—Myalgia—Docetaxel—skin cancer	3.26e-05	0.000302	CcSEcCtD
Everolimus—Arthralgia—Docetaxel—skin cancer	3.26e-05	0.000302	CcSEcCtD
Everolimus—Chest pain—Docetaxel—skin cancer	3.26e-05	0.000302	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—NRAS—skin cancer	3.25e-05	0.0021	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—IL6—skin cancer	3.25e-05	0.0021	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—KRAS—skin cancer	3.24e-05	0.00209	CbGpPWpGaD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	3.24e-05	0.0003	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—NRAS—skin cancer	3.22e-05	0.00208	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—IL6—skin cancer	3.22e-05	0.00208	CbGpPWpGaD
Everolimus—Diarrhoea—Temozolomide—skin cancer	3.21e-05	0.000298	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—NRAS—skin cancer	3.21e-05	0.00207	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—skin cancer	3.21e-05	0.00207	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—KRAS—skin cancer	3.19e-05	0.00206	CbGpPWpGaD
Everolimus—Hypersensitivity—Fluorouracil—skin cancer	3.19e-05	0.000295	CcSEcCtD
Everolimus—Dry mouth—Docetaxel—skin cancer	3.19e-05	0.000295	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—SHH—skin cancer	3.15e-05	0.00203	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—RASA1—skin cancer	3.13e-05	0.00202	CbGpPWpGaD
Everolimus—Oedema—Docetaxel—skin cancer	3.12e-05	0.000289	CcSEcCtD
Everolimus—Dizziness—Temozolomide—skin cancer	3.11e-05	0.000288	CcSEcCtD
Everolimus—Infection—Docetaxel—skin cancer	3.1e-05	0.000287	CcSEcCtD
Everolimus—Nausea—Dactinomycin—skin cancer	3.09e-05	0.000286	CcSEcCtD
Everolimus—Shock—Docetaxel—skin cancer	3.07e-05	0.000285	CcSEcCtD
Everolimus—Nervous system disorder—Docetaxel—skin cancer	3.06e-05	0.000284	CcSEcCtD
Everolimus—Pruritus—Fluorouracil—skin cancer	3.06e-05	0.000283	CcSEcCtD
Everolimus—Thrombocytopenia—Docetaxel—skin cancer	3.06e-05	0.000283	CcSEcCtD
Everolimus—Tachycardia—Docetaxel—skin cancer	3.05e-05	0.000282	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—KRAS—skin cancer	3.05e-05	0.00197	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—NRAS—skin cancer	3.04e-05	0.00196	CbGpPWpGaD
Everolimus—Skin disorder—Docetaxel—skin cancer	3.03e-05	0.000281	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—KRAS—skin cancer	3.03e-05	0.00196	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—skin cancer	3.03e-05	0.00196	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—KRAS—skin cancer	3.02e-05	0.00195	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—KRAS—skin cancer	3e-05	0.00194	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTCH1—skin cancer	2.99e-05	0.00193	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SMO—skin cancer	2.99e-05	0.00193	CbGpPWpGaD
Everolimus—Vomiting—Temozolomide—skin cancer	2.99e-05	0.000276	CcSEcCtD
Everolimus—Anorexia—Docetaxel—skin cancer	2.98e-05	0.000276	CcSEcCtD
Everolimus—Rash—Temozolomide—skin cancer	2.96e-05	0.000274	CcSEcCtD
Everolimus—Diarrhoea—Fluorouracil—skin cancer	2.96e-05	0.000274	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—skin cancer	2.96e-05	0.00191	CbGpPWpGaD
Everolimus—Dermatitis—Temozolomide—skin cancer	2.96e-05	0.000274	CcSEcCtD
Everolimus—Headache—Temozolomide—skin cancer	2.94e-05	0.000272	CcSEcCtD
Everolimus—Hypotension—Docetaxel—skin cancer	2.92e-05	0.00027	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PTGER4—skin cancer	2.91e-05	0.00188	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—skin cancer	2.91e-05	0.00188	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—HRAS—skin cancer	2.88e-05	0.00186	CbGpPWpGaD
Everolimus—Dizziness—Fluorouracil—skin cancer	2.86e-05	0.000265	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—skin cancer	2.85e-05	0.00184	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Docetaxel—skin cancer	2.85e-05	0.000263	CcSEcCtD
Everolimus—MTOR—BDNF signaling pathway—HRAS—skin cancer	2.83e-05	0.00183	CbGpPWpGaD
Everolimus—Insomnia—Docetaxel—skin cancer	2.83e-05	0.000262	CcSEcCtD
Everolimus—MTOR—DAP12 interactions—KRAS—skin cancer	2.83e-05	0.00182	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—skin cancer	2.83e-05	0.00182	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—KRAS—skin cancer	2.83e-05	0.00182	CbGpPWpGaD
Everolimus—Paraesthesia—Docetaxel—skin cancer	2.81e-05	0.00026	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—KRAS—skin cancer	2.8e-05	0.00181	CbGpPWpGaD
Everolimus—Nausea—Temozolomide—skin cancer	2.79e-05	0.000258	CcSEcCtD
Everolimus—Dyspnoea—Docetaxel—skin cancer	2.79e-05	0.000258	CcSEcCtD
Everolimus—Somnolence—Docetaxel—skin cancer	2.78e-05	0.000257	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—KRAS—skin cancer	2.78e-05	0.00179	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—KRAS—skin cancer	2.76e-05	0.00178	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—IL6—skin cancer	2.76e-05	0.00178	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—HRAS—skin cancer	2.76e-05	0.00178	CbGpPWpGaD
Everolimus—Vomiting—Fluorouracil—skin cancer	2.75e-05	0.000255	CcSEcCtD
Everolimus—Dyspepsia—Docetaxel—skin cancer	2.75e-05	0.000255	CcSEcCtD
Everolimus—Rash—Fluorouracil—skin cancer	2.73e-05	0.000253	CcSEcCtD
Everolimus—Dermatitis—Fluorouracil—skin cancer	2.73e-05	0.000252	CcSEcCtD
Everolimus—Decreased appetite—Docetaxel—skin cancer	2.72e-05	0.000251	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—HRAS—skin cancer	2.71e-05	0.00175	CbGpPWpGaD
Everolimus—Headache—Fluorouracil—skin cancer	2.71e-05	0.000251	CcSEcCtD
Everolimus—Gastrointestinal disorder—Docetaxel—skin cancer	2.7e-05	0.00025	CcSEcCtD
Everolimus—Fatigue—Docetaxel—skin cancer	2.69e-05	0.000249	CcSEcCtD
Everolimus—Constipation—Docetaxel—skin cancer	2.67e-05	0.000247	CcSEcCtD
Everolimus—Pain—Docetaxel—skin cancer	2.67e-05	0.000247	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—IL6—skin cancer	2.64e-05	0.0017	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—KRAS—skin cancer	2.61e-05	0.00169	CbGpPWpGaD
Everolimus—FKBP1A—Disease—ERCC2—skin cancer	2.61e-05	0.00169	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GLI2—skin cancer	2.61e-05	0.00168	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—HRAS—skin cancer	2.6e-05	0.00168	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—IL6—skin cancer	2.6e-05	0.00168	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—HRAS—skin cancer	2.59e-05	0.00167	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—HRAS—skin cancer	2.58e-05	0.00166	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—skin cancer	2.58e-05	0.00166	CbGpPWpGaD
Everolimus—Feeling abnormal—Docetaxel—skin cancer	2.57e-05	0.000238	CcSEcCtD
Everolimus—Nausea—Fluorouracil—skin cancer	2.57e-05	0.000238	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—FOXO4—skin cancer	2.57e-05	0.00166	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—HRAS—skin cancer	2.57e-05	0.00166	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Docetaxel—skin cancer	2.55e-05	0.000236	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—HRAS—skin cancer	2.55e-05	0.00165	CbGpPWpGaD
Everolimus—MTOR—Disease—ENO2—skin cancer	2.53e-05	0.00163	CbGpPWpGaD
Everolimus—MTOR—Disease—SHH—skin cancer	2.53e-05	0.00163	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—skin cancer	2.52e-05	0.00162	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—skin cancer	2.5e-05	0.00162	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MC1R—skin cancer	2.49e-05	0.00161	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—IL6—skin cancer	2.48e-05	0.0016	CbGpPWpGaD
Everolimus—Body temperature increased—Docetaxel—skin cancer	2.47e-05	0.000229	CcSEcCtD
Everolimus—Abdominal pain—Docetaxel—skin cancer	2.47e-05	0.000229	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—IL6—skin cancer	2.47e-05	0.00159	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—IL6—skin cancer	2.46e-05	0.00159	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GLI1—skin cancer	2.45e-05	0.00158	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TERT—skin cancer	2.45e-05	0.00158	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—IL6—skin cancer	2.44e-05	0.00158	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—HRAS—skin cancer	2.4e-05	0.00155	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HRAS—skin cancer	2.4e-05	0.00155	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—skin cancer	2.4e-05	0.00155	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—HRAS—skin cancer	2.38e-05	0.00154	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—HRAS—skin cancer	2.36e-05	0.00152	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—HRAS—skin cancer	2.35e-05	0.00152	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SUFU—skin cancer	2.32e-05	0.0015	CbGpPWpGaD
Everolimus—Hypersensitivity—Docetaxel—skin cancer	2.3e-05	0.000213	CcSEcCtD
Everolimus—MTOR—DAP12 interactions—IL6—skin cancer	2.3e-05	0.00148	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—skin cancer	2.3e-05	0.00148	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—IL6—skin cancer	2.3e-05	0.00148	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—IL6—skin cancer	2.28e-05	0.00147	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—IL6—skin cancer	2.26e-05	0.00146	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—IL6—skin cancer	2.25e-05	0.00145	CbGpPWpGaD
Everolimus—Asthenia—Docetaxel—skin cancer	2.24e-05	0.000207	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—NRAS—skin cancer	2.24e-05	0.00144	CbGpPWpGaD
Everolimus—MTOR—Immune System—FOXO4—skin cancer	2.23e-05	0.00144	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—HRAS—skin cancer	2.22e-05	0.00143	CbGpPWpGaD
Everolimus—Pruritus—Docetaxel—skin cancer	2.21e-05	0.000205	CcSEcCtD
Everolimus—Diarrhoea—Docetaxel—skin cancer	2.14e-05	0.000198	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	2.13e-05	0.00137	CbGpPWpGaD
Everolimus—Dizziness—Docetaxel—skin cancer	2.07e-05	0.000191	CcSEcCtD
Everolimus—MTOR—Disease—FOXO4—skin cancer	2.06e-05	0.00133	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	2.04e-05	0.00131	CbGpPWpGaD
Everolimus—Vomiting—Docetaxel—skin cancer	1.99e-05	0.000184	CcSEcCtD
Everolimus—Rash—Docetaxel—skin cancer	1.97e-05	0.000182	CcSEcCtD
Everolimus—Dermatitis—Docetaxel—skin cancer	1.97e-05	0.000182	CcSEcCtD
Everolimus—Headache—Docetaxel—skin cancer	1.96e-05	0.000181	CcSEcCtD
Everolimus—FKBP1A—Disease—BRAF—skin cancer	1.94e-05	0.00125	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—KRAS—skin cancer	1.92e-05	0.00124	CbGpPWpGaD
Everolimus—Nausea—Docetaxel—skin cancer	1.86e-05	0.000172	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—TP53—skin cancer	1.82e-05	0.00118	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SHH—skin cancer	1.77e-05	0.00114	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—RASA1—skin cancer	1.76e-05	0.00114	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TERT—skin cancer	1.72e-05	0.00111	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTCH1—skin cancer	1.68e-05	0.00108	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SMO—skin cancer	1.68e-05	0.00108	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—IL6—skin cancer	1.67e-05	0.00108	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—HRAS—skin cancer	1.64e-05	0.00106	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTGER4—skin cancer	1.64e-05	0.00106	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—skin cancer	1.57e-05	0.00101	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—IL6—skin cancer	1.57e-05	0.00101	CbGpPWpGaD
Everolimus—MTOR—Disease—ERCC2—skin cancer	1.47e-05	0.000949	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FOXO4—skin cancer	1.44e-05	0.000933	CbGpPWpGaD
Everolimus—MTOR—Disease—TERT—skin cancer	1.38e-05	0.00089	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—BRAF—skin cancer	1.36e-05	0.000877	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—NRAS—skin cancer	1.28e-05	0.000823	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NRAS—skin cancer	1.22e-05	0.000791	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NRAS—skin cancer	1.22e-05	0.000787	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—skin cancer	1.1e-05	0.000709	CbGpPWpGaD
Everolimus—MTOR—Disease—BRAF—skin cancer	1.09e-05	0.000705	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—skin cancer	1.05e-05	0.000681	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—skin cancer	1.05e-05	0.000678	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLIN2—skin cancer	1.03e-05	0.000662	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TERT—skin cancer	9.65e-06	0.000623	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—skin cancer	9.33e-06	0.000602	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—skin cancer	8.96e-06	0.000579	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—IL6—skin cancer	8.93e-06	0.000577	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—skin cancer	8.92e-06	0.000576	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—skin cancer	8.82e-06	0.000569	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRAS—skin cancer	8.54e-06	0.000551	CbGpPWpGaD
Everolimus—FKBP1A—Disease—IL6—skin cancer	8.54e-06	0.000551	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CSPG4—skin cancer	8.27e-06	0.000534	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—BRAF—skin cancer	7.64e-06	0.000493	CbGpPWpGaD
Everolimus—MTOR—Immune System—NRAS—skin cancer	7.43e-06	0.00048	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—skin cancer	7.35e-06	0.000475	CbGpPWpGaD
Everolimus—MTOR—Disease—NRAS—skin cancer	6.86e-06	0.000443	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—skin cancer	6.53e-06	0.000422	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—skin cancer	6.39e-06	0.000413	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—skin cancer	6.25e-06	0.000403	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL6—skin cancer	5.98e-06	0.000386	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—skin cancer	5.9e-06	0.000381	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENO2—skin cancer	5.62e-06	0.000363	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—skin cancer	5.43e-06	0.000351	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL6—skin cancer	5.2e-06	0.000336	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—skin cancer	5.02e-06	0.000324	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRAS—skin cancer	4.8e-06	0.00031	CbGpPWpGaD
Everolimus—MTOR—Disease—IL6—skin cancer	4.8e-06	0.00031	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—skin cancer	4.13e-06	0.000267	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—skin cancer	3.67e-06	0.000237	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—skin cancer	3.51e-06	0.000227	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL6—skin cancer	3.36e-06	0.000217	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ERCC2—skin cancer	3.27e-06	0.000211	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—skin cancer	1.96e-06	0.000126	CbGpPWpGaD
